October 17, 2023
Diakonos Oncology is a clinical-stage biotechnology company, developing a novel "Double-Loaded" Dendritic Cell Vaccine (DCV) for the treatment of Glioblastoma Multiforme (GBM) as well as other difficult to treat cancer indications. Leveraging a patented multi-step process, Diakonos' DCV protocol initiates powerful and unique TH1 immunity against the patient's tumor. With statistically significant efficacy already achieved in unmethylated GBM, Diakonos Oncology's approach is poised to transform the landscape of cancer treatment. In addition, Diakonos' DCV protocol has had no observed off-target effects to date.
CEO/Top Company Official
Mike Wicks (firstname.lastname@example.org)
Lead Product in Development
"Double-Loaded" Dendritic Cell Vaccine for Glioblastoma Multiforme (GBM)
Number Of Unlicensed Products